CN102292097B - 染料木黄酮的晶型 - Google Patents

染料木黄酮的晶型 Download PDF

Info

Publication number
CN102292097B
CN102292097B CN200980155203.5A CN200980155203A CN102292097B CN 102292097 B CN102292097 B CN 102292097B CN 200980155203 A CN200980155203 A CN 200980155203A CN 102292097 B CN102292097 B CN 102292097B
Authority
CN
China
Prior art keywords
genistein
crystalline
salt
sodium salt
salt dihydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980155203.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102292097A (zh
Inventor
安德斯·贝肯斯塔姆
斯特凡·伦马克
迈克尔-罗宾·威特
基思·洛里默
史蒂芬·沃特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axcentua Pharmaceuticals AB
Original Assignee
Axcentua Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcentua Pharmaceuticals AB filed Critical Axcentua Pharmaceuticals AB
Priority to CN201510205311.6A priority Critical patent/CN104860913B/zh
Publication of CN102292097A publication Critical patent/CN102292097A/zh
Application granted granted Critical
Publication of CN102292097B publication Critical patent/CN102292097B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
CN200980155203.5A 2008-12-11 2009-12-11 染料木黄酮的晶型 Expired - Fee Related CN102292097B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510205311.6A CN104860913B (zh) 2008-12-11 2009-12-11 染料木黄酮的晶型

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12178708P 2008-12-11 2008-12-11
US12177808P 2008-12-11 2008-12-11
US61/121,787 2008-12-11
US61/121,778 2008-12-11
PCT/US2009/067664 WO2010068861A1 (en) 2008-12-11 2009-12-11 Crystalline forms of genistein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510205311.6A Division CN104860913B (zh) 2008-12-11 2009-12-11 染料木黄酮的晶型

Publications (2)

Publication Number Publication Date
CN102292097A CN102292097A (zh) 2011-12-21
CN102292097B true CN102292097B (zh) 2015-05-27

Family

ID=42243089

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510205311.6A Expired - Fee Related CN104860913B (zh) 2008-12-11 2009-12-11 染料木黄酮的晶型
CN200980155203.5A Expired - Fee Related CN102292097B (zh) 2008-12-11 2009-12-11 染料木黄酮的晶型

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201510205311.6A Expired - Fee Related CN104860913B (zh) 2008-12-11 2009-12-11 染料木黄酮的晶型

Country Status (11)

Country Link
US (2) US9012495B2 (enExample)
EP (1) EP2373326B1 (enExample)
JP (3) JP5898958B2 (enExample)
KR (2) KR20110106355A (enExample)
CN (2) CN104860913B (enExample)
AU (1) AU2009324489B2 (enExample)
BR (1) BRPI0923504A2 (enExample)
CA (1) CA2746652C (enExample)
IL (2) IL213473A (enExample)
WO (1) WO2010068861A1 (enExample)
ZA (1) ZA201105045B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
US9012495B2 (en) 2008-12-11 2015-04-21 Axcentua Pharmaceuticals Ab Crystalline forms of genistein
WO2011104667A1 (en) * 2010-02-25 2011-09-01 Anthem Biosciences Private Limited Basic aminoacid salts of polyphenols
CN102442989B (zh) * 2010-10-12 2015-04-08 上海睿智化学研究有限公司 一种金雀异黄素盐、其晶体及其制备方法
CN102442991B (zh) * 2010-10-12 2015-03-11 上海睿智化学研究有限公司 一种金雀异黄素维生素b6共晶、其晶体及其制备方法
CN102442990B (zh) * 2010-10-12 2015-03-11 上海睿智化学研究有限公司 一种金雀异黄素烟酰胺共晶、其晶体及其制备方法
CN105963246B (zh) * 2016-05-06 2018-12-25 荆楚理工学院 一种染料木素盐口服溶液剂及制备方法和应用
CN105853350A (zh) * 2016-05-24 2016-08-17 荆楚理工学院 一种染料木素溶液及制备方法和应用
CN109666014A (zh) * 2018-12-12 2019-04-23 荆门医药工业技术研究院 一种染料木素衍生物盐的制备方法及其应用
EP4255415A1 (en) 2020-12-03 2023-10-11 Delta 4 GmbH Genistein for use in the treatment of focal segmental glomerulosclerosis (fsgs)
AU2023261942A1 (en) 2022-04-28 2024-09-19 GreenStone Biosciences, Inc. Treatment of the adverse cardiovascular effects of cannabinoids
WO2025117337A1 (en) 2023-11-28 2025-06-05 GreenStone Biosciences, Inc. Genistein phosphate derivatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4841077A (en) * 1985-11-18 1989-06-20 Yamanouchi Pharmaceutical Co., Ltd. Isoflavone derivatives, and salts thereof, and cancerocidal and immunosuppressive agents containing the same
WO2002081491A2 (en) * 2001-04-09 2002-10-17 Instytut Farmaceutyczny New genistein derivatives and pharmaceutical preparations containing them

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830887A (en) 1992-05-19 1998-11-03 Novogen Research Pty. Ltd. Health supplements containing phyto-oestrogens, analogues or metabolites thereof
DE4331233A1 (de) 1993-09-15 1995-03-16 Basf Ag Verfahren zur Herstellung von Hydroxyoxaalkylmelaminen
US5569459A (en) * 1995-02-15 1996-10-29 Bio-Virus Research Incorporated Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders
US5554519A (en) 1995-08-07 1996-09-10 Fermalogic, Inc. Process of preparing genistein
PL179170B1 (pl) * 1995-09-15 2000-07-31 Inst Lekow Nowe zwiazki,pochodne genisteiny PL PL PL PL
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
GB9613455D0 (en) 1996-06-27 1996-08-28 Aston Molecules Ltd Analogues or derivatives of quercetin
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US5981775A (en) 1998-09-16 1999-11-09 Board Of Trustees Operating Michigan State University Process for the preparation of isoflavones
US6194469B1 (en) * 1998-12-11 2001-02-27 Board Of Trustees Operating Michigan State Univeristy Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AUPQ520300A0 (en) * 2000-01-21 2000-02-17 Novogen Research Pty Ltd Food product and process
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
DE60010450T2 (de) 2000-06-16 2005-05-12 Linnea S.A., Riazzino Wasserlöslicher Komplex eines Ginkgo biloba-Extrakts, Verfahren zu dessen Herstellung und diesen enthaltende Zusammensetzung
BR0112225A (pt) 2000-07-07 2003-05-06 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
US6541613B2 (en) * 2000-12-15 2003-04-01 Uyrex Corporation Isoflavone derivatives
CN100348592C (zh) * 2001-12-28 2007-11-14 中国人民解放军第二军医大学 3，7，8－三取代－5－羟基苯并－γ－吡喃酮类化合物及其制备方法
US20040023981A1 (en) 2002-07-24 2004-02-05 Yu Ren Salt forms with tyrosine kinase activity
PT1578755E (pt) 2002-12-24 2007-10-19 Astrazeneca Ab Derivados de fosfonooxiquinazolina e sua utilização farmacêutica
US7803786B2 (en) * 2004-06-17 2010-09-28 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions and related methods of use
DE602004028113D1 (de) 2004-07-20 2010-08-26 Furfural Espanol S A Verwendung von 2,3-Dehydronaringenin-Derivaten zur Behandlung von Entzündungsprozessen und diese Derivate enthaltende pharmazeutische Zusammensetzung
WO2006087164A1 (en) 2005-02-15 2006-08-24 Dsm Ip Assets B.V. Compositions containing polysaccharides
ES2369928T3 (es) * 2005-06-29 2011-12-09 Dsm Ip Assets B.V. Nanopartículas de isoflavonas y su utilización.
EP1921916A2 (en) 2005-08-11 2008-05-21 The Scripps Research Institute Genistein inhibition of transthyretin amyloidosis
WO2007061254A1 (en) 2005-11-25 2007-05-31 B & C Biopharm. Co., Ltd. Genistein derivatives and anti-fungal composition containing the same
WO2008034016A2 (en) 2006-09-15 2008-03-20 Foldrx Pharmaceuticals, Inc. Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
JP2008094751A (ja) * 2006-10-11 2008-04-24 Ono Pharmaceut Co Ltd プランルカスト水和物含有医薬組成物
US9012495B2 (en) 2008-12-11 2015-04-21 Axcentua Pharmaceuticals Ab Crystalline forms of genistein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4841077A (en) * 1985-11-18 1989-06-20 Yamanouchi Pharmaceutical Co., Ltd. Isoflavone derivatives, and salts thereof, and cancerocidal and immunosuppressive agents containing the same
WO2002081491A2 (en) * 2001-04-09 2002-10-17 Instytut Farmaceutyczny New genistein derivatives and pharmaceutical preparations containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
染料木黄酮的研究进展;李明等;《西南国防医药》;20080430;第18卷(第4期);617-620 *

Also Published As

Publication number Publication date
AU2009324489B2 (en) 2015-11-12
HK1164698A1 (en) 2012-09-28
BRPI0923504A2 (pt) 2020-05-26
US20120035253A1 (en) 2012-02-09
US9012495B2 (en) 2015-04-21
CN102292097A (zh) 2011-12-21
CA2746652C (en) 2018-03-06
EP2373326B1 (en) 2016-03-09
JP2017061566A (ja) 2017-03-30
JP2015193630A (ja) 2015-11-05
KR20170091177A (ko) 2017-08-08
AU2009324489A1 (en) 2011-07-28
KR101849059B1 (ko) 2018-04-13
CN104860913B (zh) 2018-05-04
IL213473A0 (en) 2011-07-31
IL213473A (en) 2014-12-31
JP6067781B2 (ja) 2017-01-25
WO2010068861A1 (en) 2010-06-17
IL235943A0 (en) 2015-01-29
CN104860913A (zh) 2015-08-26
EP2373326A4 (en) 2012-09-05
US9492425B2 (en) 2016-11-15
US20150290166A1 (en) 2015-10-15
EP2373326A1 (en) 2011-10-12
JP5898958B2 (ja) 2016-04-06
ZA201105045B (en) 2012-10-31
KR20110106355A (ko) 2011-09-28
CA2746652A1 (en) 2010-06-17
JP2012512164A (ja) 2012-05-31

Similar Documents

Publication Publication Date Title
CN102292097B (zh) 染料木黄酮的晶型
CN108884080B (zh) 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用
CN113698356B (zh) 新型parp抑制剂的稳定晶型及其制备方法
CN110291079A (zh) 与吡啶酰基哌啶5-ht1f激动剂相关的组合物和方法
US7863325B2 (en) Crystalline genistein sodium salt dihydrate
TWI540131B (zh) 阿瑞吡坦（ａｐｒｅｐｉｔａｎｔ）ｌ－脯胺酸組成物及共晶體
JP6178799B2 (ja) アプレピタントｌ−プロリン溶媒和化合物−組成物及び共結晶
JP2023512621A (ja) フルバチニブ又はそのメタンスルホン酸塩の結晶形およびその製造方法
EA023238B1 (ru) Замещенные производные индола для лечения иммунологических расстройств
CN114401720A (zh) 多酪氨酸激酶抑制剂的晶型、制备方法及其用途
WO2022171117A1 (zh) 含氮稠杂环化合物的盐、晶型及其制备方法、药物组合物和用途
HK1164698B (en) Crystalline forms of genistein
US20210380586A1 (en) 2-indolyl imidazo[4,5-d]phenanthroline polymorphs and compositions regarding the same
WO2024125591A1 (zh) 苯并恶嗪酮类化合物的结晶及其制备
KR20150079665A (ko) 치환된 인돌 유도체
TW202543633A (zh) 喹唑啉酮衍生物的晶型及其製備方法和應用
WO2016169030A1 (zh) 吡啶胺化合物的富马酸盐及其晶体
WO2022199699A1 (zh) 含氮稠杂环化合物的盐的晶型及其制备方法和应用
CN120344512A (zh) 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
CN118541361A (zh) 1-磺酰基吡咯衍生物的新型盐、其制备方法和包括其的药物组合物
CN120965677A (zh) 一种Sparsentan晶型DCI及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1164698

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1164698

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150527

Termination date: 20191211

CF01 Termination of patent right due to non-payment of annual fee